Connect to other sites within the UBM Medica Network
The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
We Don't Control the Numbers
While we are increasingly evaluated on numbers—A1c, blood pressure, LDL—these parameters are largely outside of our direct control. Mr M is a case in point.
7 Important Questions on Using SGLT2 Inhibitors in Elderly Patients
There are pros and cons to using SGLT2 inhibitors in the elderly. Are you familiar with both? Find out with 7 quick multiple choice questions.
Type 2 Diabetes in a 76-Year-Old Man: Which Drug to Add On?
John is an active older man whose A1c has gone from 6.8% to 7.6% since his last follow-up visit. He refuses to get involved in any “needle business.” What’s next?
SGLT2 Inhibitor Q & A
Four questions for you to answer, four facts you need to know.
Worthless Wake-up Calls
When is a lab critical value a true critical value? That is the question that needs to be answered so that we can put an end to 5 am phone calls from the lab--to me.
Four Facts to Remember Before Prescribing a GLP-1 Agonist
Exenatide, dulaglitide, albiglutide, liraglutide. Can you answer these four questions on the facts about the glucagon-like receptor-1 receptor agonists?
ADA 2015 Updates Standards of Care
The American Diabetes Association has adopted the 2013 ACC/AHA cholesterol guidelines in its 2015 Standards of Care -- but not entirely.
Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
By clicking Accept, you agree to become a member of the UBM Medica Community.